



Participant of ASX Group and holder of Australian
Financial Services Licence No 236048

FREE Outperforming Stock Picks | **LATEST BREAKING NEWS: ACCC** gives interim approval to AWB and G



SHAW
Online

Adviser
Online

Headline News
MarketWatch
▶ News & Views
Warrants
Economics
Stock Ideas
Corporate Diary

Financial Products
Managed Funds
Float Files

Columns
Feature
ToKnights Bulletin
Nelson's Column
Open Briefing
Pierpont


Markets
Prices & Charts

egoli Services
Book Shop
Education
Join egoli Hotlist
Contact egoli

SHAW Stockbroking
About SHAW
Become a Client
Research
Products & Services
▶ SHAW AFS Licence
Contact SHAW

CyGenics open new Singapore facility

7/10/04 By: Stephen Blaxhall



Stem cell biotechnology and immunotherapy company CyGenics L (CYN) today announced that its tissue bank subsidiary, CordLife, opened its second tissue processing and storage facility in Singapore. The new facility is valued at S\$1.7 million, provides double the storage capacity of the existing laboratory and is located next to the company's existing facility at Camden Medical Center.



The new laboratory is the first of its kind in the region and meets current GMP (Good Manufacturing Practices) and American Association of Blood Banks (AABB) requirements, the company statement said.

CyGenics also said they believe the new facility would help towards full AABB accreditation. Outside of the United States, so far only seven cord blood banks worldwide have achieved this accreditation.

"After over two years' of operations, I'm glad to say that we have not had a single incidence of contamination in the lab," said Soren Bested, chief technology officer and laboratory director talking about the company's record.

"With this new laboratory, we are confident of maintaining this excellent record.

"As importantly, we are confident our processes are able to achieve the highest possible of viable cells for storage and possible future use," added Mr Bested.


The company is due to start stem cell expansion clinical trials in Australia soon the company statement advised.

At 1138 AEST **CyGenics** were **up 2c** at **\$1.01**.





CYN - CYGENICS LIMITED



[Disclaimer](#) [Contact SHAW](#) [Technical Help](#) [P](#)
SHAW Stockbroking Sydney - 1800 636 625 Melbourne - 180 009